>Genmab Announces Phase III Results for DLBCL Treatment

by

Epcoritamab Combination Therapy Shows Promising Results in Relapsed/Refractory DLBCL Positive results from Arm 10 of teh Phase Ib/II EPCORE NHL-2 trial demonstrate the potential of combining the T-cell engaging bispecific antibody epcoritamab with rituximab,ifosfamide,carboplatin,and etoposide (R-ICE) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). AbbVie and Genmab announced the findings on january

Source link

Related posts:

  1. Fungal Peritoneal Dialysis-Associated Peritonitis as a Silent Threat: The Critical Role of Early Diagnosis and Catheter Removal – Cureus
  2. Beauvais Hospital Revolutionizes Cancer Care with State-of-the-Art Machinery
  3. New drug class may help alleviate IBS symptoms by targeting the central nervous system
  4. Radiotherapy: Shorter Treatments, Same Results

Leave a Comment